Edwards Lifesciences price target raised to $75 from $70 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $70 and keeps an Equal Weight rating on the shares. Given the recent analyst day, there were “few surprises” on the FY25 outlook, says the analyst, who thinks investors are next likely to focus on the SAPIEN M3 mitral replacement product launch in the EU in mid-2025.